Skip to content

Study · Randomized controlled trial · n = 1,879 · 2026

13 results

Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.

Neves JS, Leite AR, Vale C, Marques P, Vasques-Nóvoa F, Leite-Moreira A, Ferreira JP

Diabetologia19 Dec 2025

PMID41419618 (opens in a new tab)DOI10.1007/s00125-025-06637-7 (opens in a new tab)PepBankPUB-41419618
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, all tirzepatide doses increased the number of standard therapeutic targets achieved versus semaglutide at 40 weeks.

    In plain wordsIn adults with type 2 diabetes, tirzepatide helped more people reach standard health targets than semaglutide did.

    Peptide
    Tirzepatide
    Outcome
    IncreaseNumber of standard therapeutic targets achieved
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    All doses of tirzepatide increased the number of achieved standard and intensive targets compared with semaglutide.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, all tirzepatide doses increased the number of intensive therapeutic targets achieved versus semaglutide at 40 weeks.

    In plain wordsIn adults with type 2 diabetes, tirzepatide helped more people reach strict health targets than semaglutide did.

    Peptide
    Tirzepatide
    Outcome
    IncreaseNumber of intensive therapeutic targets achieved
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    All doses of tirzepatide increased the number of achieved standard and intensive targets compared with semaglutide.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide increased the odds of reaching HbA1c below 7% versus semaglutide (OR 1.50).

    In plain wordsIn adults with type 2 diabetes, tirzepatide gave higher odds than semaglutide of reaching an HbA1c below 7%.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c below 7% (53 mmol/mol)
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Odds ratio
    1.5 ratio
    tirzepatide vs semaglutide, HbA1c <7%

    Source sentences

    Summary
    HbA1c <53 mmol/mol [7%], OR 1.50 [95% CI 1.12, 2.00]
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide increased the odds of reaching HbA1c below 6.5% versus semaglutide (OR 1.88).

    In plain wordsIn adults with type 2 diabetes, tirzepatide gave higher odds than semaglutide of reaching an HbA1c below 6.5%.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c below 6.5% (48 mmol/mol)
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Odds ratio
    1.88 ratio
    tirzepatide vs semaglutide, HbA1c <6.5%

    Source sentences

    Summary
    HbA1c <48 mmol/mol [6.5%], OR 1.88 [95%CI 1.49, 2.36]
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide increased the odds of losing more than 10% of body weight versus semaglutide (OR 2.72).

    In plain wordsIn adults with type 2 diabetes, tirzepatide gave higher odds than semaglutide of losing more than 10% of body weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss above 10%
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Odds ratio
    2.72 ratio
    tirzepatide vs semaglutide, weight loss >10%

    Source sentences

    Summary
    weight loss >10%, OR 2.72 [95% CI 2.14, 3.47]
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide increased the odds of losing more than 15% of body weight versus semaglutide (OR 3.86).

    In plain wordsIn adults with type 2 diabetes, tirzepatide gave higher odds than semaglutide of losing more than 15% of body weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss above 15%
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Odds ratio
    3.86 ratio
    tirzepatide vs semaglutide, weight loss >15%

    Source sentences

    Summary
    weight loss >15%, OR 3.86 [95% CI 2.69, 5.55]
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide increased the odds of reaching the intensive blood pressure target versus semaglutide (OR 1.45).

    In plain wordsIn adults with type 2 diabetes, tirzepatide gave higher odds than semaglutide of reaching the strict blood pressure target.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIntensive blood pressure target below 130/80 mmHg
    Study

    n = 1,879

    Comparator
    Semaglutide 1 mg
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Odds ratio
    1.45 ratio
    tirzepatide vs semaglutide, intensive BP target

    Source sentences

    Summary
    the intensive target for BP (OR 1.45 [95% CI 1.17, 1.81]
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 42% on tirzepatide 5 mg met three or more standard targets versus 34% on semaglutide.

    In plain wordsIn adults with type 2 diabetes, 42% on tirzepatide 5 mg met three or more standard targets, compared with 34% on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMeeting three or more standard targets, 5 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more standard targets
    42%
    tirzepatide 5 mg
    Met 3 or more standard targets
    34%
    semaglutide 1 mg

    Source sentences

    Summary
    For standard targets, 34% of participants treated with semaglutide met three or more targets, compared with 42%, 53% and 57% with tirzepatide 5, 10 and 15 mg, respectively.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 53% on tirzepatide 10 mg met three or more standard targets versus 34% on semaglutide.

    In plain wordsIn adults with type 2 diabetes, 53% on tirzepatide 10 mg met three or more standard targets, compared with 34% on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMeeting three or more standard targets, 10 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more standard targets
    53%
    tirzepatide 10 mg
    Met 3 or more standard targets
    34%
    semaglutide 1 mg

    Source sentences

    Summary
    For standard targets, 34% of participants treated with semaglutide met three or more targets, compared with 42%, 53% and 57% with tirzepatide 5, 10 and 15 mg, respectively.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 57% on tirzepatide 15 mg met three or more standard targets versus 34% on semaglutide.

    In plain wordsIn adults with type 2 diabetes, 57% on tirzepatide 15 mg met three or more standard targets, compared with 34% on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMeeting three or more standard targets, 15 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more standard targets
    57%
    tirzepatide 15 mg
    Met 3 or more standard targets
    34%
    semaglutide 1 mg

    Source sentences

    Summary
    For standard targets, 34% of participants treated with semaglutide met three or more targets, compared with 42%, 53% and 57% with tirzepatide 5, 10 and 15 mg, respectively.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 15%, 20% and 29% on tirzepatide met three or more intensive targets versus 8% on semaglutide.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on semaglutide (8%) met three or more strict targets.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMeeting three or more intensive targets
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more intensive targets
    15%
    tirzepatide
    Met 3 or more intensive targets
    20%
    tirzepatide
    Met 3 or more intensive targets
    29%
    tirzepatide
    Met 3 or more intensive targets
    8%
    semaglutide 1 mg

    Source sentences

    Summary
    For intensive targets, 8% of participants treated with semaglutide met three or more targets, vs 15%, 20% and 29% with tirzepatide.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 34% on semaglutide 1 mg met three or more standard targets at 40 weeks, versus 42%, 53% and 57% on tirzepatide 5, 10 and 15 mg.

    In plain wordsIn adults with type 2 diabetes, 34% on semaglutide met three or more standard targets, compared with 42% to 57% on tirzepatide.

    Peptide
    Semaglutide
    Outcome
    Not applicableMeeting three or more standard targets
    Study

    n: not reported in source

    Comparator
    Tirzepatide 5, 10 or 15 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more standard targets
    34%
    semaglutide 1 mg

    Source sentences

    Summary
    For standard targets, 34% of participants treated with semaglutide met three or more targets, compared with 42%, 53% and 57% with tirzepatide 5, 10 and 15 mg, respectively.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 8% on semaglutide 1 mg met three or more intensive targets at 40 weeks, versus 15%, 20% and 29% on tirzepatide.

    In plain wordsIn adults with type 2 diabetes, 8% on semaglutide met three or more strict targets, compared with 15% to 29% on tirzepatide.

    Peptide
    Semaglutide
    Outcome
    Not applicableMeeting three or more intensive targets
    Study

    n: not reported in source

    Comparator
    Tirzepatide 5, 10 or 15 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · 40 weeksAs given in this study (human).

    Measurements

    Met 3 or more intensive targets
    8%
    semaglutide 1 mg

    Source sentences

    Summary
    For intensive targets, 8% of participants treated with semaglutide met three or more targets, vs 15%, 20% and 29% with tirzepatide.
    2 context sentences
    Summary · context
    We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.
    Summary · context
    Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.